Active clinical trials combining radiation with TGF-β blockade or GM-CSF

NCT Number	Phases	Title	Condition	Intervention	RT Details	Enrollment	Sponsor/Collaborators
Anti-TGF- β
NCT02538471	Phase 2	LY2157299 Monohydrate (LY2157299) and Radiotherapy in Metastatic Breast Cancer	Metastatic Breast Cancer	LY2157299	RT, 7.5 Gy × 3 fx	28	Weill Medical College of Cornell University\|University of California, Los Angeles
NCT02581787	Phase 1\|Phase 2	SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer	Stage IA-B NSCLC	Fresolimumab	SBRT, 4 fx	60	Maximilian Diehn\|National Cancer Institute (NCI)\|Stanford University
GM-CSF
NCT02623595	Phase 2	A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy	Non-small cell lung cancer	GM-CSF	SBRT, 10 Gy × 5 fx	60	Wuhan University\|Tongji Hospital\|Hubei Cancer Hospital
NCT02663440	Phase 2	Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme	Glioblastoma	GM-CSF, Temozolomide	Hypofx IMRT	41	Zhejiang Cancer Hospital
NCT02677155	Phase 2	Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma	Follicular Lymphoma	GM-CSF, Pembrolizumab, Rituximab, autologous dendritic cells	8 Gy × 1	20	Oslo University Hospital\|Norwegian Cancer Society\|Merck Sharp & Dohme Corp.
NCT02648282	Phase 2	Study With CY, Pembrolizumab, GVAX, and SBRT in Patients With Locally Advanced Pancreatic Cancer	Pancreatic Cancer	GVAX, Cyclophosphamide, Pembrolizumab	SBRT, 6.6 Gy × 5 fx	54	Sidney Kimmel Comprehensive Cancer Center\|Merck Sharp & Dohme Corp.

Abbreviations: GM-CSF granulocyte macrophage colony stimulating factor, Hypofx hypofractionated, IMRT intensity modulated radiation therapy, NSCLC non-small cell lung cancer, SBRT stereotactic body radiation therapy